Arcturus Therapeutics is trading at $14.41, down 5.10%, after profit-taking following an unusually strong rally.
- Shares rose from $10.28 on August 19 to $16.17 on August 27; recent coverage linked the advance to messenger-RNA enthusiasm and company progress.
- No major new company-specific announcement for August 31 was identified, while broader U.S. equities are modestly lower, adding cautious market pressure.